SC
FBIO icon

Sophrosyne Capital’s Fortress Biotech FBIO Stock Holding History

Sophrosyne Capital’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,300
Closed -$1.59M – 68
2013
Q2 		$1.59M Buy
+12,300
New +$1.81M 1.25% 23

Other funds holding FBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return

Sophrosyne Capital's FBIO Position: Q3 2013 in Review

Sophrosyne Capital sold out of Fortress Biotech (FBIO) in Q3 2013, closing a stake of 12,300 shares — an estimated $1.59M sold.

Sophrosyne Capital first reported a position in FBIO in Q2 2013 and held it in 1 quarter. The position peaked at $1.59M in Q2 2013. 81 funds tracked by Wall St. Rank hold FBIO as of Q3 2013.

  • Sophrosyne Capital reported no remaining Fortress Biotech position as of Q3 2013 after selling out during the quarter.
  • Sophrosyne Capital sold 12,300 Fortress Biotech shares in Q3 2013, an estimated $1.59M.
  • Sophrosyne Capital first reported a position in Fortress Biotech in Q2 2013 and held it in 1 quarter.
  • Sophrosyne Capital's Fortress Biotech position peaked at $1.59M in Q2 2013.
  • 81 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2013.

Based on Sophrosyne Capital's 13F filing for Q3 2013, filed 14 Nov 2013.